Input-specific plasticity at excitatory synapses mediated by endocannabinoids in the dentate gyrus.
Endocannabinoids (eCBs) mediate transient and long-lasting synaptic plasticity in several brain structures. In the dentate gyrus, activation of the type 1 cannabinoid receptor (CB1R) by exogenous ligands reportedly depresses excitatory synaptic transmission. However, direct evidence of eCB signaling at excitatory synapses in this region has been lacking. Here, we demonstrate that eCB release can be induced by a brief postsynaptic depolarization of dentate granule cells (DGCs), which potently and transiently suppresses glutamatergic inputs from mossy cell interneurons (MCs) but not from entorhinal cortex via the lateral and medial perforant paths. This input-specific depolarization-induced suppression of excitation (DSE) is calcium-dependent and can be modulated by agonists of cholinergic and group I metabotropic glutamate receptors. Inhibiting the synthesis of 2-arachidonoyl glycerol (2-AG), one of the most abundant eCBs in the brain, by diacyglycerol lipase (DGL) does not abolish DSE. Moreover, preventing the breakdown of anandamide, the other main eCB, does not potentiate DSE. Thus, eCB signaling underlying DSE in the dentate does not require DGL activity and is unlikely to be mediated by anandamide. Finally, we find that manipulations known to induce eCB-LTD at other central synapses do not trigger LTD at MCF-DGC synapses.
Chiu
Chiayu Q
CQ
Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Castillo
Pablo E
PE
D000818:Animals; D000831:Animals, Newborn; D001095:Arachidonic Acids / Q000378:metabolism; D048588:Benzoxazines / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism*; D018678:Cholinergic Agents / Q000494:pharmacology; D018891:Dentate Gyrus / Q000166:cytology*; D004558:Electric Stimulation; D063388:Endocannabinoids; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects / Q000502:physiology* / Q000528:radiation effects; D005989:Glycerides / Q000378:metabolism; D066298:In Vitro Techniques; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009025:Morpholines / Q000494:pharmacology; D009281:Naphthalenes / Q000494:pharmacology; D009434:Neural Pathways / Q000502:physiology; D009473:Neuronal Plasticity / Q000187:drug effects / Q000502:physiology* / Q000528:radiation effects; D009474:Neurons / Q000502:physiology*; D018408:Patch-Clamp Techniques; D051381:Rats; D017208:Rats, Wistar; D043884:Receptor, Cannabinoid, CB1 / Q000172:deficiency / Q000502:physiology
D001095:Arachidonic Acids; D048588:Benzoxazines; D002121:Calcium Channel Blockers; D063385:Cannabinoid Receptor Modulators; D018678:Cholinergic Agents; D063388:Endocannabinoids; D005989:Glycerides; D009025:Morpholines; D009281:Naphthalenes; D043884:Receptor, Cannabinoid, CB1; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; C094503:glyceryl 2-arachidonate; D002118:Calcium
Br J Pharmacol. 2004 May;142(1):9-19
15100161
J Neurophysiol. 1995 Jul;74(1):179-94
7472322
Nat Neurosci. 2004 Jul;7(7):697-8
15184902
Biochem Pharmacol. 2004 Nov 1;68(9):1691-8
15450934
Neuron. 2004 Sep 30;44(1):5-21
15450156
Brain Res. 1981 May 18;212(2):287-300
7225870
J Comp Neurol. 1985 Sep 8;239(2):237-46
4044938
Neuroscience. 1989;31(3):571-91
2687721
Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932-6
2308954
Cereb Cortex. 1993 Mar-Apr;3(2):133-47
8490319
Hippocampus. 1992 Oct;2(4):349-62
1284975
J Neurosci. 1994 May;14(5 Pt 2):3106-21
8182460
Ann Neurol. 1994 Jun;35(6):640-54
8210220
J Comp Neurol. 1996 Mar 4;366(2):271-92
8698887
J Neurophysiol. 1996 Dec;76(6):3798-806
8985877
J Comp Neurol. 1997 Apr 14;380(3):382-94
9087520
J Neurosci. 1997 Oct 1;17(19):7503-22
9295396
Neuroscience. 1998 Mar;83(2):393-411
9460749
J Comp Neurol. 1998 Oct 26;400(3):391-407
9779943
Proc Natl Acad Sci U S A. 1999 May 11;96(10):5780-5
10318961
J Neurosci. 1999 Nov 1;19(21):9519-29
10531454
J Neurosci. 2001 Dec 15;21(24):RC188
11734603
Trends Neurosci. 2002 Mar;25(3):140-4
11852145
Eur J Neurosci. 2002 Mar;15(6):953-61
11918654
Curr Opin Neurobiol. 2002 Jun;12(3):324-30
12049940
Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8384-8
12060781
Mol Neurobiol. 2002 Oct-Dec;26(2-3):317-46
12428763
J Neurosci. 2002 Dec 1;22(23):10182-91
12451119
Prog Neurobiol. 2002 Nov;68(4):247-86
12498988
Nat Med. 2003 Jan;9(1):76-81
12461523
Neuron. 2003 May 8;38(3):461-72
12741992
Physiol Rev. 2003 Jul;83(3):1017-66
12843414
Eur J Neurosci. 2003 Jul;18(1):109-16
12859343
Neuron. 2003 Aug 14;39(4):599-611
12925275
Neuron. 2003 Aug 14;39(4):641-54
12925278
J Neurophysiol. 2003 Oct;90(4):2536-47
14534276
Br J Pharmacol. 2003 Nov;140(5):781-9
14504143
Nat Rev Neurosci. 2003 Nov;4(11):873-84
14595399
J Cell Biol. 2003 Nov 10;163(3):463-8
14610053
J Neurosci. 1999 Jun 1;19(11):4544-58
10341254
Neuroscience. 1999;92(1):61-71
10392830
J Neurosci. 2004 Nov 3;24(44):9953-61
15525780
Nat Neurosci. 2005 Sep;8(9):1139-41
16116451
J Physiol. 2005 Sep 15;567(Pt 3):1001-10
16037085
J Neurosci. 2005 Nov 9;25(45):10537-45
16280591
Neuron. 2005 Nov 23;48(4):647-59
16301180
J Neurophysiol. 2006 Jan;95(1):67-75
16207781
J Neurosci. 2006 Mar 15;26(11):2991-3001
16540577
J Neurosci. 2006 Apr 19;26(16):4166-77
16624937
Neuroscience. 2006;139(3):795-802
16527424
J Neurosci. 2006 May 24;26(21):5628-37
16723519
J Neurosci. 2006 May 24;26(21):5794-9
16723537
J Endocrinol Invest. 2006;29(3 Suppl):3-14
16751705
Annu Rev Neurosci. 2006;29:37-76
16776579
Neuron. 2006 Aug 17;51(4):455-66
16908411
J Physiol. 2006 Nov 15;577(Pt 1):263-80
16973696
J Neurosci. 2007 Jan 31;27(5):1211-9
17267577
J Neurosci. 2007 May 9;27(19):5260-4
17494712
J Neurosci. 2004 May 19;24(20):4865-74
15152047